Sub-acute demyelinating neuropathy associated with an NK/T cell lymphoma.
Wills
A J
AJ
O'Connor
S
S
McMillan
A
A
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001706:Biopsy; D003520:Cyclophosphamide / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003711:Demyelinating Diseases / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005158:Facial Paralysis / Q000175:diagnosis / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D008279:Magnetic Resonance Imaging; D008727:Methotrexate / Q000008:administration & dosage; D009460:Neurologic Examination; D009852:Omentum / Q000473:pathology; D020364:Paraneoplastic Polyneuropathy / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D013126:Spinal Nerve Roots / Q000473:pathology; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D007069:Ifosfamide; D008727:Methotrexate